Galecto Prices Upsized Public Offering to Fund DMR-001

Galecto ( (GLTO) ) has provided an update.

On February 10, 2026, Galecto, Inc. entered into an underwriting agreement with Jefferies and Leerink Partners for a public offering of 14,473,685 shares of common stock at $19.00 per share, and the underwriters fully exercised a 30-day option on February 11, 2026 to purchase an additional 2,171,052 shares. The deal, conducted under an automatic shelf registration, is expected to close on February 12, 2026 and will provide approximately $295.9 million in net proceeds, which, together with existing cash, are expected to fund operations into Phase 3 development of DMR-001, while Galecto also agreed to standard indemnification provisions for the underwriters.

The offering, supported by a legal validity opinion from Gibson, Dunn & Crutcher, strengthens Galecto’s balance sheet and extends its funding runway toward a key late-stage milestone for DMR-001, which is critical for the company’s clinical and strategic trajectory. However, management cautions that the capital-use timeline is based on assumptions that may prove incorrect, indicating potential variability in how long the new financing will sustain operations.

The most recent analyst rating on (GLTO) stock is a Buy with a $31.00 price target. To see the full list of analyst forecasts on Galecto stock, see the GLTO Stock Forecast page.

Spark’s Take on GLTO Stock

According to Spark, TipRanks’ AI Analyst, GLTO is a Neutral.

The score is held back primarily by weak fundamentals (no revenue, ongoing losses, and continued cash burn despite improvement) and unattractive earnings-based valuation (negative P/E). Offsetting factors include strong technical momentum (price above key moving averages with positive MACD) and positive corporate developments (Damora acquisition and associated financing extending runway).

To see Spark’s full report on GLTO stock, click here.

More about Galecto

Galecto, Inc. is a biopharmaceutical company focused on developing drug candidates, including its program DMR-001, with an emphasis on advancing these assets through late-stage clinical development. The company operates in the U.S. capital markets and uses public equity offerings to finance its research and development pipeline and ongoing operations.

Average Trading Volume: 208,963

Technical Sentiment Signal: Buy

Current Market Cap: $38.34M

See more data about GLTO stock on TipRanks’ Stock Analysis page.